Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ZyVersa Therapeutics, Inc. - Common Stock (NQ:ZVSA)

0.3113 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ZyVersa Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
From ZyVersa Therapeutics
Via GlobeNewswire
Why TransMedics Group Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
Shares of TransMedics Group, Inc. (NASDAQ: TMDX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial results and issued strong guidance. 
Via Benzinga
Why Freshpet Shares Are Trading Higher By Around 15%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Freshpet, Inc. (NASDAQ: FRPT) gained 15.5% to $106.29 after the company reported better-than-expected fourth-quarter financial results. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
What In The World Is Going On With ZyVersa Therapeutics (ZVSA) Stock?
ZyVersa Therapeutics shares are trading higher by 126% Monday. The stock continues to be volatile after the company last week released a white paper. 
Via Benzinga
US Stocks Edge Higher; Domino's Posts Upbeat Earnings
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 50 points on Monday. Following the market opening Monday, the Dow traded up 0.04% 39,148.74 while the NASDAQ rose... 
Via Benzinga
Topics Stocks
Why Is Intuitive Machines (LUNR) Stock Down 23% Today?
Intuitive Machines stock is falling on Monday as investors in LUNR react to an update on the company's lunar landing last week. 
Via InvestorPlace
Why Is Aclarion (ACON) Stock Down 19% Today?
Aclarion stock is falling on Monday as investors react to news of a public offering for shares of ACON and a delisting update. 
Via InvestorPlace
Why Is Freight Technologies (FRGT) Stock Up 25% Today?
Freight Technologies stock is heading higher on Monday with heavy trading of FRGT alongside a collaboration deal with Envases Universales. 
Via InvestorPlace
Why Intuitive Machines Shares Are Trading Lower By Around 30%; Here Are 20 Stocks Moving Premarket
Shares of Intuitive Machines, Inc. (NASDAQ: LUNR) fell sharply in today’s pre-market trading. Intuitive Machines revealed Friday that its lunar lander, Odysseus, encountered a mishap during a touchdown... 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today?
ZyVersa Therapeutics stock is rising higher on Monday as shares of ZVDA experience heavy pre-market trading this morning. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
We're starting the trading week with a breakdown of the biggest pre-market stock movers traders need to know about on Monday morning! 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases
From ZyVersa Therapeutics
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer’s Disease
From ZyVersa Therapeutics
Via GlobeNewswire
Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of KeyCorp (NYSE: KEY) moved lower during Thursday’s session after the company reported fourth-quarter financial results. Revenues of $1.538 billion, down 19.0% Y/Y, slightly topped the... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Why Is Inflammatory Disease-Focused ZyVersa Therapeutics Stock Trading Higher Today?
ZyVersa reveals study in Acta Neuropathologica Communications. Learn how inhibiting NLRP3 inflammasome with Inflammasome ASC Inhibitor IC 100 prevents TNBC brain metastasis. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics’ CEO, Stephen C. Glover, Featured on Benzinga All Access
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets
From ZyVersa Therapeutics
Via GlobeNewswire
ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024
From ZyVersa Therapeutics
Via GlobeNewswire
This Biotech Is Targeting Indications Worth $70 Billion
Stephen C. Glover, Co-founder, Chairman, CEO and President of ZyVersa Therapeutics Inc. (NASDAQ: ZVSA) was recently a guest on Benzinga’s All-Access. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS